menu
    • menu
    [{"orgOrder":0,"company":"PolarityTE","sponsor":"Alira Health","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dermal","sponsorNew":"PolarityTE \/ Alira Health","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Alira Health"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Professional Education and Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dermal","sponsorNew":"PolarityTE \/ Professional Education and Research Institute","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Professional Education and Research Institute"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Podiatry","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dermal","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Inapplicable"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Phase III","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PolarityTE \/ Inapplicable"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||Undisclosed","graph1":"Dermatology","graph2":"IND Enabling","graph3":"PolarityTE","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PolarityTE \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"PolarityTE \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PolarityTE

    Menu

    PolarityTE

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SkinTE,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PolarityBio Receives FDA Breakthrough Therapy for Wagner Grade I DFU

                            Details : SkinTE is a human cellular tissue-based product derived from patient's own skin to regenerate full-thickness, functionally-polarized skin. Being investigated for wagner grade 1 diabetic foot ulcers.

                            Product Name : SkinTE

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 20, 2025

                            Lead Product(s) : SkinTE,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Skinte,Inapplicable

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Professional Education and Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SkinTE® for the Treatment of Wagner 1 Diabetic Foot Ulcers (COVER DFUS II)

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            November 18, 2023

                            Lead Product(s) : Skinte,Inapplicable

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Professional Education and Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Skinte,Inapplicable

                            Therapeutic Area : Podiatry

                            Study Phase : Phase III

                            Sponsor : Alira Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 13, 2022

                            Lead Product(s) : Skinte,Inapplicable

                            Therapeutic Area : Podiatry

                            Highest Development Status : Phase III

                            Sponsor : Alira Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SkinTE,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PolarityTE Provides Update on Investigational New Drug Application

                            Details : SkinTE® is the only FDA-registered product that is capable of regenerating full-thickness skin with all layers and appendage with a proposed indication for chronic cutaneous ulcers.

                            Product Name : SkinTE

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 10, 2021

                            Lead Product(s) : SkinTE,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            PolarityTE

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SkinTE,Inapplicable

                            Therapeutic Area : Podiatry

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE™ Diabetic Foot Ulcer Trial

                            Details : The data show a statistically significant difference favoring PolarityTE’s autologous skin construct, SkinTE, in the primary endpoint of wounds closed at 12 weeks, and in percent area reduction of wounds at each time point measured.

                            Product Name : SkinTE

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            July 24, 2020

                            Lead Product(s) : SkinTE,Inapplicable

                            Therapeutic Area : Podiatry

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth